These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37170778)

  • 21. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients.
    Kyrgidis A; Tzellos TG; Toulis K; Arora A; Kouvelas D; Triaridis S
    Curr Clin Pharmacol; 2013 May; 8(2):124-34. PubMed ID: 23092218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
    Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
    Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
    Khan AA; Morrison A; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Al Dabagh R; Davison KS; Kendler DL; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Bone Miner Res; 2015 Jan; 30(1):3-23. PubMed ID: 25414052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
    Bassatne A; Bou Khalil A; Chakhtoura M; Arabi A; Van Poznak C; El-Hajj Fuleihan G
    Metabolism; 2022 Mar; 128():154962. PubMed ID: 34958816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical benefits of bone targeted agents in early breast cancer.
    Coleman R
    Breast; 2019 Nov; 48 Suppl 1():S92-S96. PubMed ID: 31839171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
    Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
    Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.
    Ota S; Inoue R; Shiozaki T; Yamamoto Y; Hashimoto N; Takeda O; Yoshikawa K; Ito J; Ishibashi Y
    Breast Cancer; 2017 Jul; 24(4):601-607. PubMed ID: 27943163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw.
    Yasui T; Kimura M; Nagamine H; Yajima S; Karube T; Sato H; Asoda S; Hara S; Onizawa K
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Mar; 131(3):312-318. PubMed ID: 33431343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
    Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
    Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication-related osteonecrosis of the jaw: A literature review.
    Kuroshima S; Sasaki M; Sawase T
    J Oral Biosci; 2019 Jun; 61(2):99-104. PubMed ID: 31109863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of bone health in women with estrogen receptor-positive breast cancer receiving endocrine therapy.
    Malagrinò M; Zavatta G
    Womens Health (Lond); 2023; 19():17455057221149493. PubMed ID: 36644991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.